Study identifier:CD-ON-MEDI-575-1042
ClinicalTrials.gov identifier:NCT01268566
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 2 Study of MEDI-575 in Adult Subjects with Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Phase 2
No
MEDI-575
All
62
Interventional
18 Years - 95 Years
Allocation: N/A
Endpoint Classification: Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Feb 2017 by MedImmune, LLC
MedImmune, LLC
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: MEDI-575, 25 mg/kg MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal. | Drug: MEDI-575 MEDI-575 as an IV infusion. |